Patents by Inventor Evelyne Janzek-Hawlat
Evelyne Janzek-Hawlat has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230340148Abstract: The present invention relates to a method for treating a GD2 positive cancer by administering a preparation comprising an anti-GD2 antibody to a patient as a continuous intravenous infusion over 24 hours per day.Type: ApplicationFiled: September 19, 2022Publication date: October 26, 2023Applicant: APEIRON BIOLOGICS AGInventors: Hans LOIBNER, Manfred SCHUSTER, Evelyne JANZEK-HAWLAT, Susanne WIEDERKUM, Bernhard PEBALL, Stefan STRANNER, Oliver MUTSCHLECHNER, Franz GROISS, Ruth LADENSTEIN, Holger LODE
-
Patent number: 11447565Abstract: The present invention relates to a method for treating a GD2 positive cancer by administering a preparation comprising an anti-GD2 antibody to a patient as a continuous intravenous infusion over 24 hours per day.Type: GrantFiled: September 11, 2017Date of Patent: September 20, 2022Assignee: APEIRON BIOLOGICS AGInventors: Hans Loibner, Manfred Schuster, Evelyne Janzek-Hawlat, Susanne Wiederkum, Bernhard Peball, Stefan Stranner, Oliver Mutschlechner, Franz Groiss, Ruth Ladenstein, Holger Lode
-
Patent number: 10716833Abstract: The present invention relates to recombinant ACE2 polypeptide, where the ACE2 polypeptide is present as a dimer. The dimer is formed specifically from glycosylated monomers and is used for producing pharmaceutical products with an extended half-life.Type: GrantFiled: December 6, 2017Date of Patent: July 21, 2020Assignee: APEIRON BIOLOGICS AGInventors: Manfred Schuster, Hans Loibner, Evelyne Janzek-Hawlat, Bernhard Peball, Stefan Stranner, Bettina Wagner, Robert Weik
-
Publication number: 20180289779Abstract: The present invention relates to recombinant ACE2 polypeptide, where the ACE2 polypeptide is present as a dimer.Type: ApplicationFiled: December 6, 2017Publication date: October 11, 2018Inventors: Manfred Schuster, Hans Loibner, Evelyne Janzek-Hawlat, Bernhard Peball, Stefan Stranner, Bettina Wagner, Robert Weik
-
Publication number: 20180134801Abstract: The present invention relates to a method for treating a GD2 positive cancer by administering a preparation comprising an anti-GD2 antibody to a patient as a continuous intravenous infusion over 24 hours per day.Type: ApplicationFiled: September 11, 2017Publication date: May 17, 2018Applicant: APEIRON BIOLOGICS AGInventors: Hans LOIBNER, Manfred SCHUSTER, Evelyne JANZEK-HAWLAT, Susanne WIEDERKUM, Bernhard PEBALL, Stefan STRANNER, Oliver MUTSCHLECHNER, Franz GROISS, Ruth LADENSTEIN, Holger LODE
-
Patent number: 9777068Abstract: The present invention relates to a method for treating a GD2 positive cancer by administering a preparation comprising an anti-GD2 antibody to a patient as a continuous intravenous infusion over 24 hours per day.Type: GrantFiled: July 31, 2012Date of Patent: October 3, 2017Assignee: APEIRON BIOLOGICS AGInventors: Hans Loibner, Manfred Schuster, Evelyne Janzek-Hawlat, Susanne Wiederkum, Bernhard Peball, Stefan Stranner, Oliver Mutschlechner, Franz Groiss, Ruth Ladenstein, Holger Lode
-
Publication number: 20150139942Abstract: The present invention relates to a method for treating a GD2 positive cancer by administering a preparation comprising an anti-GD2 antibody to a patient as a continuous intravenous infusion over 24 hours per day.Type: ApplicationFiled: July 31, 2012Publication date: May 21, 2015Applicant: APEIRON BIOLOGICS AGInventors: Hans Loibner, Manfred Schuster, Evelyne Janzek-Hawlat, Susanne Wiederkum, Bernhard Peball, Stefan Stranner, Oliver Mutschlechner, Franz Groiss, Ruth Ladenstein, Holger Lode
-
Patent number: 8946162Abstract: The invention provides for innovative improvements in tumor therapy, particularly therapies which are conducted using endogenous substances and which have no or only mild side-effects. Accordingly the present invention relates to methods of treating or preventing tumor diseases other than lung cancer comprising administering a polypeptide with an angiotensin-converting-enzyme-2 (ACE2) activity.Type: GrantFiled: April 7, 2009Date of Patent: February 3, 2015Inventors: Evelyne Janzek-Hawlat, Hans Loibner, Manfred Schuster, Bernhard Peball
-
Publication number: 20140099297Abstract: The present invention relates to recombinant ACE2 polypeptide, where the ACE2 polypeptide is present as a dimer.Type: ApplicationFiled: September 13, 2013Publication date: April 10, 2014Applicant: Apeiron Biologics AGInventors: Manfred Schuster, Hans Loibner, Evelyne Janzek-Hawlat, Bernhard Peball, Stefan Stranner, Bettina Wagner, Robert Weik
-
Patent number: 8586319Abstract: The present invention relates to recombinant ACE2 polypeptide, where the ACE2 polypeptide is present as a dimer. The dimer is formed specifically from glycosylated monomers and is used for producing pharmaceutical products with an extended half-life.Type: GrantFiled: June 12, 2008Date of Patent: November 19, 2013Assignee: Apeiron Biologics AGInventors: Manfred Schuster, Hans Loibner, Evelyne Janzek-Hawlat, Bernhard Peball, Stefan Stranner, Bettina Wagner, Robert Weik
-
Patent number: 8241864Abstract: Methods of determining ACE2 activity in a sample by reacting the sample with ACE2-binding units immobilized on a solid carrier and specific for a part of ACE2 not involved in the catalytic activity of ACE2. The reaction provides a signal that can be correlated with the ACE2 activity. These methods allow for ACE2 activity in complex solutions, such as bodily liquids or culture supernatants, to be quantitatively determined using the endogenous activity of the enzyme to be quantified by converting a signal-providing substrate.Type: GrantFiled: October 19, 2007Date of Patent: August 14, 2012Assignee: Apeiron Biologics Forschungs-und Entwicklungsgesellschaft m.b.H.Inventors: Hans Loibner, Manfred Schuster, Evelyne Janzek-Hawlat
-
Publication number: 20110033524Abstract: The invention provides for innovative improvements in tumour therapy, particularly therapies which are conducted using endogenous substances and which have no or only mild side-effects. Accordingly the present invention relates to methods of treating or preventing tumor diseases other than lung cancer comprising administering a polypeptide with an angiotensin-converting-enzyme-2 (ACE2) activity.Type: ApplicationFiled: April 7, 2009Publication date: February 10, 2011Inventors: Evelyne Janzek-hawlat, Hans Loibner, Manfred Schuster, Bernhard Peball
-
Publication number: 20100310546Abstract: The present invention relates to recombinant ACE2 polypeptide, where the ACE2 polypeptide is present as a dimer. The dimer is formed specifically from glycosylated monomers and is used for producing pharmaceutical products with an extended half-life.Type: ApplicationFiled: June 12, 2008Publication date: December 9, 2010Applicant: APEIRON BIOLOGICS AGInventors: Manfred Schuster, Hans Loibner, Evelyne Janzek-Hawlat, Bernhard Peball, Stefan Stranner, Bettina Wagner, Robert Weik
-
Publication number: 20100261214Abstract: The present invention relates to a method of determining ACE2 activity, comprising the following steps: providing ACE2-binding units immobilized on a solid carrier and specific for a part of ACE2 which is not involved in the catalytic activity of ACE2; contacting the immobilized ACE2-binding units with a sample which potentially includes the ACE2, wherein the ACE2 is bound by the ACE2-binding unit; removing the non-binding portions of the sample from the ACE2 bound to the ACE2-binding units; adding a substrate of the ACE2 which is reacted by the ACE2 activity, with the reaction providing a signal; and measuring the change in the signal during a specific period of time, wherein the change can be correlated with the ACE2 activity.Type: ApplicationFiled: October 19, 2007Publication date: October 14, 2010Applicant: Apeiron Biologics Forschungs- Und Entwicklungsgese llschaft M.B.H.Inventors: Hans Loibner, Manfred Schuster, Evelyne Janzek-Hawlat